Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
IRVINE, California, October 29 /PRNewswire-FirstCall/ -- IsoTis, Inc. (NASDAQ:ISOT) ("IsoTis"), an orthobiologics company, today announced that, at the special meeting of stockholders...
IRVINE, California, October 29 /PRNewswire-FirstCall/ -- IsoTis, Inc. (NASDAQ:ISOT) ("IsoTis"), an orthobiologics company, today announced that, at the special meeting of stockholders...
Less Than 40,000 Additional "FOR" Votes Required for Integra Merger IRVINE, California, October 26 /PRNewswire-FirstCall/ -- IsoTis, Inc. (NASDAQ:ISOT) ("IsoTis"), an orthobiologics company...
Less Than 100,000 Additional "FOR" Votes Required for Integra Merger IRVINE, California, October 26 /PRNewswire-FirstCall/ -- IsoTis, Inc. (NASDAQ:ISOT) ("IsoTis"), an orthobiologics company...
Less Than 350,000 Additional Votes "FOR" Required for Integra Merger IRVINE, California, October 24 /PRNewswire-FirstCall/ -- IsoTis, Inc. (NASDAQ:ISOT) ("IsoTis"), an orthobiologics company...
Conference Calls to Answer Questions About Stockholder Meeting October 23 IRVINE, California, October 16 /PRNewswire-FirstCall/ -- IsoTis, Inc. (NASDAQ:ISOT) ("IsoTis"), an orthobiologics...
IRVINE, California, October 16 /PRNewswire-FirstCall/ -- - Conference Calls to Answer Questions About Stockholder Meeting October 23 IsoTis, Inc. (NASDAQ:ISOT) ("IsoTis"), an orthobiologics...
IRVINE, California, October 11 /PRNewswire-FirstCall/ -- IsoTis, Inc. (NASDAQ:ISOT) ("IsoTis"), an orthobiologics company, today announced that it has adjourned the special meeting of...
Leading Proxy Advisor Recommends Shareholders Support Merger IRVINE, California, September 19 /PRNewswire-FirstCall/ -- IsoTis, Inc. (NASDAQ:ISOT) ("IsoTis"), an orthobiologics company, today...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
